drugset / Trial / NCT00006981
Immunotoxin Therapy in Treating Patients With Advanced Cancer
Open-labelTreatment
Summary
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for advanced cancer. PURPOSE: Phase I trial to study the effectiveness of immunotoxins in treating patients who have advanced cancer.
Timeline
- Start
- 2000-12
- Primary completion
- —
- Completion
- —
Publications
- Results Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res. 2009 Aug 15;15(16):5274-9. doi: 10.1158/1078-0432.CCR-09-0062. Epub 2009 Aug 11.
- Results Hassan R, Kreitman R, Strauss L, et al.: SS1(dsFv)-PE38 anti-mesothelin immunotoxin in advanced malignancies: phase I and pharmacokinetic study of alternate-day infusion. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-113, 2002.
- Results Kreitman R, Squires D, O'Hagan D, et al.: SS1(dsFv)-PE38 anti-mesothelin immunotoxin in advanced malignancies: phase I study of continuous infusion. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1896, 2002.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SS1P | Protein / enzyme biologic | 4 ug/kg | Intravenous |
| Subject | SS1P | Protein / enzyme biologic | 8 ug/kg | Intravenous |
| Subject | SS1P | Protein / enzyme biologic | 12 ug/kg | Intravenous |
| Subject | SS1P | Protein / enzyme biologic | 18 ug/kg | Intravenous |
| Subject | SS1P | Protein / enzyme biologic | 25 ug/kg | Intravenous |